Atara Biotherapeutics (ATRA) Receives Buy Rating from Mizuho

Mizuho restated their buy rating on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a report published on Sunday, AnalystRatings.com reports. They currently have a $62.00 price target on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the stock. ValuEngine cut shares of Atara Biotherapeutics from a strong-buy rating to a buy rating in a report on Wednesday, April 10th. BidaskClub upgraded shares of Atara Biotherapeutics from a hold rating to a buy rating in a report on Thursday, February 7th. Cowen reiterated a buy rating on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. William Blair restated an outperform rating on shares of Atara Biotherapeutics in a report on Monday, April 1st. Finally, Zacks Investment Research cut shares of Atara Biotherapeutics from a hold rating to a sell rating in a report on Monday, March 4th. Three analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. Atara Biotherapeutics currently has a consensus rating of Hold and a consensus price target of $49.00.

NASDAQ ATRA opened at $33.23 on Friday. Atara Biotherapeutics has a 52 week low of $27.85 and a 52 week high of $54.45. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -6.31 and a beta of 2.25.



Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.44). Equities analysts forecast that Atara Biotherapeutics will post -5.99 earnings per share for the current fiscal year.

In related news, EVP Christopher Haqq sold 12,375 shares of the company’s stock in a transaction on Wednesday, February 6th. The shares were sold at an average price of $38.62, for a total value of $477,922.50. Following the completion of the sale, the executive vice president now owns 282,903 shares in the company, valued at approximately $10,925,713.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Joel S. Marcus sold 62,590 shares of the company’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $36.07, for a total transaction of $2,257,621.30. Following the completion of the sale, the director now owns 32,590 shares of the company’s stock, valued at approximately $1,175,521.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 154,724 shares of company stock valued at $5,796,503. Company insiders own 10.60% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC raised its position in Atara Biotherapeutics by 1.8% in the 4th quarter. FMR LLC now owns 5,274,169 shares of the biotechnology company’s stock valued at $183,225,000 after purchasing an additional 93,432 shares during the last quarter. BlackRock Inc. raised its position in Atara Biotherapeutics by 0.6% in the 4th quarter. BlackRock Inc. now owns 3,513,235 shares of the biotechnology company’s stock valued at $122,050,000 after purchasing an additional 22,453 shares during the last quarter. Vanguard Group Inc. raised its position in Atara Biotherapeutics by 4.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,487,567 shares of the biotechnology company’s stock valued at $102,861,000 after purchasing an additional 106,213 shares during the last quarter. Vanguard Group Inc raised its position in Atara Biotherapeutics by 4.5% during the 3rd quarter. Vanguard Group Inc now owns 2,487,567 shares of the biotechnology company’s stock worth $102,861,000 after buying an additional 106,213 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its position in Atara Biotherapeutics by 6.5% during the 3rd quarter. Neuberger Berman Group LLC now owns 1,218,539 shares of the biotechnology company’s stock worth $50,386,000 after buying an additional 74,833 shares during the last quarter.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also: Coverage Ratio

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.